Table 1

Patient demographics, clinical characteristics and treatment in patients with SpA fulfilling the ASAS classification criteria

Mean (SD) or n (%)
n=3370
Age, n=333442.9 (13.7)
Disease duration (years), n=33428.4 (9.5)
Male gender2221 (66)
HLA B27 positive, n=27332082 (76)
Education level, n=3364
 Primary school or less421 (13)
 Secondary school1497 (44)
 University1446 (43)
BMI (kg/m2), n=332526.1 (5.7)
Current or previous smoker, n=33651565 (46)
Sacroiliitis on X-ray, n=31902406 (75)
Sacroiliitis on MRI, n=17821249 (70)
History of enthesitis, n=33671281 (38)
History of dactylitis, n=3368463 (14)
CRP (mg/L), n=32080.51 (11)
Patient global (0–10), n=33364.1 (2.5)
BASDAI (0–10), n=33523.7 (2.4)
BASFI (0–10), n=334931 (2.7)
ASDAS (CRP), n=31552.0 (1.1)
Axial involvement (±peripheral)2955 (87.7)
History of uveitis, n=3368724 (21)
History of psoriasis, n=3369643 (19)
History of IBD, n=3366194 (6)
Extra-articular manifestations (uveitis, IBD, psoriasis)1369(41)
RDCI (0–9)0.7 (1.1)
Treatment
 NSAID intake, n=33633025(90)
 NSAID total score (past 3 months)37 (46)
 Current bDMARD/csDMARD2114 (63)
 Current bDMARD1275 (38)
 Current csDMARD1168 (35)
 Current csDMARD only839 (25)
  • ASAS, Assessment in SpondyloArthritis international Society; ASDAS, Ankylosing Spondylitis Disease Activity Score calculated with CRP; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; bDMARD, biological disease-modifying antirheumatic drugs; BMI, body mass index; CRP, C reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug.; IBD, inflammatory bowel disease; NSAID, non-steroidal anti-inflammatory drug; RDCI, Rheumatic Disease Comorbidity Index; SpA, spondyloarthritis.